Robbie Marcus
Stock Analyst at JP Morgan
(3.85)
# 707
Out of 5,042 analysts
162
Total ratings
54.95%
Success rate
8.24%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HTFL HeartFlow | Initiates: Overweight | $36 | $37.87 | -4.94% | 1 | Sep 2, 2025 | |
| COO The Cooper Companies | Maintains: Neutral | $76 → $66 | $73.51 | -10.22% | 6 | Aug 28, 2025 | |
| INSP Inspire Medical Systems | Downgrades: Neutral | $195 → $110 | $77.52 | +41.90% | 6 | Aug 5, 2025 | |
| EW Edwards Lifesciences | Maintains: Neutral | $80 → $85 | $76.10 | +11.70% | 5 | Jul 25, 2025 | |
| NPCE NeuroPace | Maintains: Overweight | $14 → $16 | $10.48 | +52.67% | 5 | May 14, 2025 | |
| CVRX CVRx, Inc. | Downgrades: Underweight | $15 → $7 | $10.45 | -33.01% | 6 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Overweight | $128 → $105 | $103.03 | +1.91% | 6 | May 6, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $12 | $16.11 | -25.51% | 6 | May 6, 2025 | |
| CNMD CONMED | Maintains: Neutral | $70 → $58 | $47.76 | +21.44% | 7 | May 1, 2025 | |
| RXST RxSight | Downgrades: Underweight | $40 → $17 | $8.61 | +97.44% | 5 | Apr 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $120 | $82.74 | +45.03% | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $36 | $23.02 | +56.39% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $381.79 | +16.56% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $546.51 | +23.51% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $6.94 | +87.32% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $110 | $101.11 | +8.79% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $320.91 | +2.83% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $12.89 | +148.25% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $37.54 | +6.55% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $85 | $70.33 | +20.86% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $78.14 | +15.18% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $32.87 | +52.11% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $6.87 | +16.45% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $252.99 | -1.18% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $8.76 | -20.09% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $15.52 | +9.54% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $126.85 | -6.98% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $180.61 | -13.63% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $93.67 | +12.10% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $74.67 | -46.43% | 2 | May 5, 2020 |
HeartFlow
Sep 2, 2025
Initiates: Overweight
Price Target: $36
Current: $37.87
Upside: -4.94%
The Cooper Companies
Aug 28, 2025
Maintains: Neutral
Price Target: $76 → $66
Current: $73.51
Upside: -10.22%
Inspire Medical Systems
Aug 5, 2025
Downgrades: Neutral
Price Target: $195 → $110
Current: $77.52
Upside: +41.90%
Edwards Lifesciences
Jul 25, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $76.10
Upside: +11.70%
NeuroPace
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $10.48
Upside: +52.67%
CVRx, Inc.
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $10.45
Upside: -33.01%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Overweight
Price Target: $128 → $105
Current: $103.03
Upside: +1.91%
Integra LifeSciences Holdings
May 6, 2025
Maintains: Underweight
Price Target: $24 → $12
Current: $16.11
Upside: -25.51%
CONMED
May 1, 2025
Maintains: Neutral
Price Target: $70 → $58
Current: $47.76
Upside: +21.44%
RxSight
Apr 4, 2025
Downgrades: Underweight
Price Target: $40 → $17
Current: $8.61
Upside: +97.44%
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $82.74
Upside: +45.03%
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $23.02
Upside: +56.39%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $381.79
Upside: +16.56%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $546.51
Upside: +23.51%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $6.94
Upside: +87.32%
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $101.11
Upside: +8.79%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $320.91
Upside: +2.83%
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $12.89
Upside: +148.25%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $37.54
Upside: +6.55%
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $70.33
Upside: +20.86%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $78.14
Upside: +15.18%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $32.87
Upside: +52.11%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $6.87
Upside: +16.45%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $252.99
Upside: -1.18%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $8.76
Upside: -20.09%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $15.52
Upside: +9.54%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $126.85
Upside: -6.98%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $180.61
Upside: -13.63%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $93.67
Upside: +12.10%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $74.67
Upside: -46.43%